Bitcoin pioneer Charlie Shrem peels back the layers on the lives and backgrounds of the world's most impactful innovators. Centering around intimate narratives, Shrem uncovers a detailed, previously unspoken story of the genesis and evolution of bitcoin, cryptocurrency, artificial intelligence, and the web3 movements. Join Shrem as he journeys through the uncharted territories of tech revolutions, revealing the human side of the stories that shaped the digital world we live in today.
…
continue reading
İçerik Proactive Investors tarafından sağlanmıştır. Bölümler, grafikler ve podcast açıklamaları dahil tüm podcast içeriği doğrudan Proactive Investors veya podcast platform ortağı tarafından yüklenir ve sağlanır. Birinin telif hakkıyla korunan çalışmanızı izniniz olmadan kullandığını düşünüyorsanız burada https://tr.player.fm/legal özetlenen süreci takip edebilirsiniz.
Player FM - Podcast Uygulaması
Player FM uygulamasıyla çevrimdışı Player FM !
Player FM uygulamasıyla çevrimdışı Player FM !
Ananda CEO outlines progress with trials, strengthened structure and improved investor sentiment
MP3•Bölüm sayfası
Manage episode 431272064 series 2891889
İçerik Proactive Investors tarafından sağlanmıştır. Bölümler, grafikler ve podcast açıklamaları dahil tüm podcast içeriği doğrudan Proactive Investors veya podcast platform ortağı tarafından yüklenir ve sağlanır. Birinin telif hakkıyla korunan çalışmanızı izniniz olmadan kullandığını düşünüyorsanız burada https://tr.player.fm/legal özetlenen süreci takip edebilirsiniz.
Ananda Developments CEO Melissa Sturgess discussed the company's recent advancements in CBD-based drug development with Proactive's Stephen Gunnion. Sturgess highlighted the progress of its clinical trials and the increasing understanding of CBD's potential in the pharmaceutical industry. She also discussed the growing distinction between over-the-counter CBD products and those being developed by Ananda, emphasising the regulatory pathway necessary for CBD medicines. Sturgess highlighted two phase two clinical trials, focusing on chemotherapy-induced pain and endometriosis, initiated by clinicians responding to patient needs. She explained the challenges and benefits of getting CBD drugs approved by the MHRA and available on the NHS, aiming to make these drugs accessible to all patients. Discussing the company's portfolio, Sturgess shared insights on their pre-clinical study using MRX1 in mice and the importance of breadth and depth in the company's research. She also talked about strengthening the company's top structure with the appointment of a scientific advisory board, chaired by Professor Clive Page, and new members, Professors Trevor Jones and Cherry Wainwright. Sturgess concluded by outlining the milestones shareholders should look for, including clinical trial progress and further study results. Visit Proactive's YouTube channel for more videos, and don't forget to give the video a like, subscribe to the channel, and enable notifications for future content. #AnandaDevelopments #CBDDrugs #ClinicalTrials #MelissaSturgess #Pharmaceuticals #CBDResearch #MHRA #NHS #InvestingInPharma #ProactiveInvestors #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
…
continue reading
608 bölüm
MP3•Bölüm sayfası
Manage episode 431272064 series 2891889
İçerik Proactive Investors tarafından sağlanmıştır. Bölümler, grafikler ve podcast açıklamaları dahil tüm podcast içeriği doğrudan Proactive Investors veya podcast platform ortağı tarafından yüklenir ve sağlanır. Birinin telif hakkıyla korunan çalışmanızı izniniz olmadan kullandığını düşünüyorsanız burada https://tr.player.fm/legal özetlenen süreci takip edebilirsiniz.
Ananda Developments CEO Melissa Sturgess discussed the company's recent advancements in CBD-based drug development with Proactive's Stephen Gunnion. Sturgess highlighted the progress of its clinical trials and the increasing understanding of CBD's potential in the pharmaceutical industry. She also discussed the growing distinction between over-the-counter CBD products and those being developed by Ananda, emphasising the regulatory pathway necessary for CBD medicines. Sturgess highlighted two phase two clinical trials, focusing on chemotherapy-induced pain and endometriosis, initiated by clinicians responding to patient needs. She explained the challenges and benefits of getting CBD drugs approved by the MHRA and available on the NHS, aiming to make these drugs accessible to all patients. Discussing the company's portfolio, Sturgess shared insights on their pre-clinical study using MRX1 in mice and the importance of breadth and depth in the company's research. She also talked about strengthening the company's top structure with the appointment of a scientific advisory board, chaired by Professor Clive Page, and new members, Professors Trevor Jones and Cherry Wainwright. Sturgess concluded by outlining the milestones shareholders should look for, including clinical trial progress and further study results. Visit Proactive's YouTube channel for more videos, and don't forget to give the video a like, subscribe to the channel, and enable notifications for future content. #AnandaDevelopments #CBDDrugs #ClinicalTrials #MelissaSturgess #Pharmaceuticals #CBDResearch #MHRA #NHS #InvestingInPharma #ProactiveInvestors #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
…
continue reading
608 bölüm
همه قسمت ها
×Player FM'e Hoş Geldiniz!
Player FM şu anda sizin için internetteki yüksek kalitedeki podcast'leri arıyor. En iyi podcast uygulaması ve Android, iPhone ve internet üzerinde çalışıyor. Aboneliklerinizi cihazlar arasında eş zamanlamak için üye olun.